Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data Boundless Bio, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2024
FY2025
Research and development
42.6
55.3
44.8
General and administrative
12.2
18
18.7
Operating expenses
54.8
73.3
63.6
Operating income
-54.8
-73.3
-63.6
Interest income
5.28
7.89
5.36
Other non-operating income
5.36
7.9
5.36
Income tax
0
0
Net income
-49.4
-65.4
-58.2
EBITDA
-53.8
-72.2
-62.3
EPS, basic
-40.65
-3.85
-2.60
EPS, diluted
-40.65
-3.85
-2.60
Shares, basic (weighted)
1.22
17
22.4
Shares, diluted (weighted)
1.22
17
22.4
Balance sheet
FY2024
FY2024
FY2025
Cash and equivalents
23.7
26.6
17.9
Short-term investments
97
126
89.7
Other current assets
3.45
2.28
2.03
Total current assets
124
154
110
Property, plant and equipment
2.57
4.32
3.22
Lease right-of-use assets
2
47
43.7
Total assets
130
206
157
Accounts payable
2.22
1.27
1.49
Accrued liabilities
2.9
2.78
2.64
Total current liabilities
9.36
8.14
12.5
Lease liabilities
47.6
45.9
Total liabilities
9.36
55.8
58.4
Paid-in capital
8.99
352
358
Retained earnings
-136
-201
-260
Other comprehensive income
0.04
0.12
0.06
Shareholders' equity
-127
151
98.7
Total equity
-127
151
98.7
Total liabilities and equity
130
206
157
Shares outstanding
0
22.3
22.4
Cash flow statement
FY2024
FY2024
FY2025
Net income
-49.4
-65.4
-58.2
Depreciation and amortization
0.96
1.09
1.25
Stock-based compensation
3.34
7.52
6.13
Deferred income tax
0
Change in payables
1.66
0.78
1.63
Cash from operations
-46.9
-60.8
-46.7
Capital expenditures
-0.63
-2.54
-0.55
Purchases of investments
-160
-208
-175
Sales and maturities of investments
122
185
213
Cash from investing
-38.3
-26.1
37.8
Stock issued
0.18
0.06
Cash from financing
97.9
89.8
0.14
Net change in cash
12.8
2.88
-8.72
Free cash flow
-47.5
-63.4
-47.2
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $2.66 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-97.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-86.8%
Net income / average total assets.
Return on invested capital (ROIC)
-117.4%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-34.5%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-23.9%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
31.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
9.48x
Current assets / current liabilities.
Quick ratio
9.35x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
9.35x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$2.53
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$2.51
Cash from operations / diluted weighted shares.
Book value per share
$2.94
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
0.92x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.92x
Market cap / tangible book value, when positive.
FCF yield
-93.8%
Free cash flow / market cap.
Earnings yield
-105.8%
Net income / market cap (the inverse of P/E).
Was Boundless Bio, Inc. profitable in fiscal 2025?
No. It reported a net loss of $58.2M.
How much free cash flow did Boundless Bio, Inc. generate in fiscal 2025?
Cash from operations of $46.7M minus capital expenditures of $546.0K left free cash flow of -$47.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.